Skip to content

Alexsandra Kovacevich

Department of Neurology, Case Western Reserve University School of Medicine, University Hospitals, Cleveland, OH, USA.

3 papers in the library · 9 citations · publishing 2023-2025

Papers

Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD

Journal of Psychoactive Drugs August 31, 2023 Alexsandra Kovacevich, Jeremy Weleff, Benjamin Claytor et al. 6 citations

Three individuals with smell loss—one from a respiratory infection, one from childhood, and one from COVID-19—reported improved olfactory function after using psychedelics: 6 g of psilocybin mushrooms, 100 µg of LSD, or microdosing 0.1 g of psilocybin mushrooms three times. These are the first such cases recorded in academic literature. Possible mechanisms include serotonergic effects, increased neuroplasticity, and anti-inflammatory actions. The authors suggest that the potential therapeutic benefits of psychedelics for olfactory impairment warrant further investigation.

Therapeutic Potential of Psilocybin for Treating Neuropsychiatric Long COVID Symptoms: A Reddit Investigation

Journal of Psychoactive Drugs March 14, 2025 Lukas Bobak, Ian Dorney, Alexsandra Kovacevich et al. 2 citations

In an analysis of 110 Reddit posts from individuals with long COVID who used psilocybin, 78.2% reported any improvement in their symptoms, while 11.8% reported worsening. Among those reporting improvement, 77.9% said the improvement lasted beyond the acute psychedelic experience, and 5.8% reported improvement only during the experience. The most common symptoms were fatigue (47.3%), cognitive impairment (46.4%), and depression (30.0%). The authors suggest that controlled studies comparing social media data for other self-treatments or prospective observational studies of individuals self-treating with psychedelics may be warranted.

Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts

Journal of Psychoactive Drugs March 1, 2025 Alexsandra Kovacevich, Ian Dorney, Lukas Bobak et al. 1 citation

Since the COVID-19 pandemic, smell loss (olfactory dysfunction) has become more common, but effective treatments are scarce. Anecdotal reports suggest that serotonergic psychedelics like LSD and psilocybin might help. Analyzing 125 online posts from people with self-reported smell loss, 108 (86.4%) reported improvements in their sense of smell after using psychedelics. Of those, 55 (50.1%) first noticed improvement during the psychedelic experience, and 42 (38.8%) said the improvement lasted at least one day. No statistical link was found between dose and how long the benefit lasted for either psilocybin or LSD. These findings indicate that further research is needed to explore whether these substances could become a clinical treatment for smell loss.